Dermira Inc (DERM) Receives Average Recommendation of “Hold” from Brokerages

Dermira Inc (NASDAQ:DERM) has been assigned an average rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $41.00.

Several equities analysts recently commented on the stock. Leerink Swann reiterated an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim began coverage on shares of Dermira in a research note on Tuesday, December 5th. They issued a “buy” rating on the stock. Mizuho dropped their target price on shares of Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th.

In related news, SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The disclosure for this sale can be found here. Insiders sold a total of 48,758 shares of company stock valued at $1,348,773 in the last ninety days. Corporate insiders own 13.30% of the company’s stock.

Institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA increased its stake in Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares in the last quarter. Quantbot Technologies LP increased its stake in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares in the last quarter. SG Americas Securities LLC increased its stake in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares in the last quarter. Legal & General Group Plc increased its stake in Dermira by 40.9% during the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares in the last quarter. Finally, Ardsley Advisory Partners acquired a new position in Dermira during the 2nd quarter valued at approximately $291,000. Institutional investors and hedge funds own 99.47% of the company’s stock.

Dermira (NASDAQ:DERM) opened at $27.35 on Monday. The company has a market cap of $1,139.79, a PE ratio of -4.39 and a beta of 0.80. Dermira has a fifty-two week low of $21.35 and a fifty-two week high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

ILLEGAL ACTIVITY WARNING: “Dermira Inc (DERM) Receives Average Recommendation of “Hold” from Brokerages” was published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/dermira-inc-derm-receives-average-recommendation-of-hold-from-brokerages/1817467.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.